Mr. Stephen Van Deventer reports

PREVECEUTICAL MEDICAL - SOL-GEL AND USES THEREOF PATENT UPDATE

Preveceutical Medical Inc. is furthering the progress of its patent family directed to Sol-Gel (international patent application No. PCT/AU2021/051383, Sol-Gel cannabinoid formulation and anti-viral use) and is taking the International patent application forward in the US and Canada, with plans to progress in Europe and Australia also.

The US patent application (USSN 18/253,573) has been filed with amended claims, together with its Canadian counterpart. Preveceutical is prosecuting the patent applications to maximize the scope of protection available in those countries and to ensure that effective and secure patents are obtained as we continue our clinical process.

Preveceutical's Chief Executive Officer, Mr. Stephen Van Deventer, commented, "We are ensuring that Sol-gel cannabinoid formulations are well protected. We continue working with government agencies, potential partners, and investors to assist in developing these anticipated therapies."

Although Preveceutical believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate or successful.

About Preveceutical

Preveceutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. The Company aims to be a leader in the preventive health sciences sector.

With the completion of three of its research programs, the Company is actively working on the development, clinical trials, and commercialization of its products; and has filed a number of provisional patent applications to protect the intellectual property from its research programs.

We seek Safe Harbor.